Disease details

Clinical trials : 3,342 / Drugs : 2,355 - (DrugBank : 406) / Drug target genes : 269 - Drug target pathways : 241

2 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01116427 (ClinicalTrials.gov)	September 2010	3/5/2010	A Cooperative Clinical Study of Abatacept in Multiple Sclerosis	A Phase II, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of Abatacept in Adults With Relapsing-remitting Multiple Sclerosis	Multiple Sclerosis, Relapsing-Remitting	Biological: abatacept;Drug: Placebo	National Institute of Allergy and Infectious Diseases (NIAID)	Immune Tolerance Network (ITN)	Completed	18 Years	65 Years	All	65	Phase 2	United States;Canada
2	NCT00035529 (ClinicalTrials.gov)	November 2001	3/5/2002	A Study to Evaluate the Preliminary Efficacy Pharmacokinetics and Immunogenicity of BMS-188667 Administered to Subjects With Relapsing-remitting Multiple Sclerosis	A Phase II,Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Preliminary Efficacy, Pharmacokinetics and Immunogenicity of BMS-188667 Administered to Subjects With Relapsing-Remitting Multiple Sclerosis	Multiple Sclerosis	Drug: Placebo;Drug: BMS 188667 (Abatacept)	Bristol-Myers Squibb	NULL	Terminated	18 Years	55 Years	Both		Phase 2	United States